Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Caen University Hospital

Status: Completed

Conditions: Cancer

Treatments: Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib

Study type: Observational

Funder types: Other

Identifiers

NCT04774406

Pharmaco 16022023

Details and patient eligibility

About

Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce.

The objective was to investigate reports of hypertension related to PARPi, including olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, and fluzoparib using the World Health Organization's (WHO) pharmacovigilance database: VigiBase.

Full description

Here, investigators use the World Health Organization's (WHO) database of individual safety case reports, to identify cases of hypertension AE related to PARPi.

Enrollment: 2,336 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• case reported in the World Health Organization (WHO) database (VigiBase) of individual safety case reports at the time of the extraction,
• patients treated with at least 1 PARPi (with ATC classification system): olaparib (ATC L01XX46), niraparib (ATC L01XX54), rucaparib (ATC L01XX55), talazoparib (ATC L01XX60), veliparib, pamiparib, fluzoparib (none).

Exclusion criteria

-chronology not compatible between the PARPi and adverse event

Trial design

2,336 participants in 1 patient group

parp inhibitors

Description:

All patients treated at least with 1 PARPi

Treatment:

Drug: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib